MedPath

LUMIERE on the PLACENTA

Withdrawn
Conditions
Pregnancy
Interventions
Other: Fetal MRI
Registration Number
NCT04166448
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Brief Summary

The frequency of IUGR is between 3 and 10% of births. The etiologies and mechanisms of IUGR are multiple. The placental insufficiency, that is the defect of perfusion, is, however, the principal mechanism, far in front of other maternal or fetal causes. This placental insufficiency is also now recognized as an essential risk factor for cardiovascular and metabolic diseases, such as diabetes, in adulthood. The interest in understanding in utero development is thus further increased by the short-, medium- and long-term consequences of placental dysfunction. However, there are few ways to evaluate uteroplacental vascularization in vivo. MRI is an imaging technique used routinely in the exploration of the fetus in addition to ultrasound. Its safety on the fetus and the mother is largely demonstrated at 1.5T. There are also MRI sequences used daily in the clinic to evaluate perfusion and organ structure in children and adults (brain, kidney, heart, etc.). Their application for evaluation of perfusion and placental structure, although still confined to research, is very promising. The investigator's team has extensive experience, in animals or in children, in the use of these sequences that could be used to evaluate placental function in vivo. The ASL (Arterial Spin Labeling) in particular is the most encouraging functional imaging technique because it allows today to measure an organ blood flow quantitatively and without injection of contrast medium.

Detailed Description

The inclusion will take place at the earliest at 20 weeks after the completion of the standard morphological ultrasound of the 2nd trimester (carried out at 20-24SA) and at the latest at 35 SA, within the framework of one of the 2 clinical subgroups of patients considered (high risk and low risk).

The objectives of this study will be achieved by the prospective setting up of a LUMIERE cohort on PLACENTA.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria
  • Singleton pregnancy without fetal malformation seen on ultrasound. Group 1: High risk IUGR patients

    • EPF<10th perc or PA<10th perc and Doppler ombilical IP> 95th percentile,
    • EPF or PA<3th perc reference curves from Collège Français d'Echographie Fœtale, between 20 et 34 GW,

Group 2: Low risk IUGR patients

• EPF et PA>20th perc reference curves from Collège Français d'Echographie Fœtale, between 20 et 34 GW

Exclusion Criteria
    • Contraindication to MRI
  • Impossible subsequent follow up
  • Maternal status contraindicates continuation of pregnancy
  • Participation in another search
  • "Protected" patient

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Group 1: High risk IUGR patientsFetal MRIEPF\<10th perc or PA\<10th perc and Doppler ombilical IP\> 95th percentile, EPF or PA\<3th perc (reference curves from Collège Français d'Echographie Fœtale, between 20 et 34 GW),
Group 2: Low risk IUGR patientsFetal MRIEPF et PA\>20th perc (reference curves from Collège Français d'Echographie Fœtale, between 20 et 34 GW)
Primary Outcome Measures
NameTimeMethod
Changes in placental blood flow as seen in vascular IUGRFrom inclusion to end of neonatal period (max 25 weeks)

25% reduction in overall placental perfusion measured ASL with IUGR (defined as \<3th perc birth weight) versus controls (birth weight\> 10th perc)

Secondary Outcome Measures
NameTimeMethod
structural changes of the placentaFrom inclusion to end of neonatal period (max 25 weeks)

T2 \* mapping

evaluation of liver resonanceFrom inclusion to end of neonatal period (max 25 weeks)

BOLD effect, - ADC coefficient and IVIM parameters by variation of T2 \* relaxation time

Uterine arteriesFrom inclusion to end of neonatal period (max 25 weeks)

Measurement of blood flow in the uterine arteries by MRI 4D FLOW (in development) and Doppler (US) (feasibility study)

Measurement of IUGR by fetal segmentation (MRI),From inclusion to end of neonatal period (max 25 weeks)

Fetal volume

evaluation of kidney resonanceFrom inclusion to end of neonatal period (max 25 weeks)

BOLD effect, - ADC coefficient and IVIM parameters by variation of T2 \* relaxation time

Acceptability of the examination for the patient: questionnaireat IRM examination

Will be assessed by a questionnaire given to pregnant women after the MRI,

Specific Absorption Rate for each type of sequenceFrom inclusion to end of neonatal period (max 25 weeks)

SAR measurement (Specific Absorption Rate)

Measurement of placental volumeFrom inclusion to end of neonatal period (max 25 weeks)

Placental segmentation

Placental response to maternal oxygenation (BOLD)From inclusion to end of neonatal period (max 25 weeks)

BOLD effect

Acceptability of the examination for the patient: Likert scaleat IRM examination

will be assessed once by a Likert scale: 4 points Likert (poor, average, good, very good)

evaluation of brain resonanceFrom inclusion to end of neonatal period (max 25 weeks)

BOLD effect, - ADC coefficient and IVIM parameters by variation of T2 \* relaxation time

Reproducibility of the examination analysisAfter study completion, an average of one year

Correlations between microcirculatory parameters in utero, fetal weight at MRI and birth weight

Trial Locations

Locations (1)

Necker - Enfants Malades Hospital

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath